Our Mission

Director of Drug Development & Strategic Innovation Partnerships

Nicolas Beuzen

A molecular biologist and geneticist by training (PhD, University of Glasgow; MSc, IAE Lyon), Nicolas brings over two decades of experience in R&D, business development, licensing, and investment across biotech and pharma in France, India, and Poland. He combines scientific insight with strategic and operational expertise to drive innovation, investment, and the successful commercialisation of life-science breakthroughs.

At Adamed Pharma, he leads collaboration frameworks, innovation sourcing, and the integration of novel opportunities into the company’s expanding R&D infrastructure and global strategy. Nicolas leverages a broad international network—from early-stage ventures to global pharma leaders, together with a pragmatic, risk-balanced mindset.

His previous roles include Director of Business Development & Licensing at Molecure, Chief Scientific Officer and Vice President of Development at Selvita (now Ryvu), and Investment Advisor at I&I Biotech Fund, where he was responsible for scouting and guiding high-potential life-science startups in Poland and the Baltics.

Director of Drug Discovery & Early Development

Bartłomiej Żerek

Graduated in Environmental Sciences with a specialization in Molecular Biology from the John Paul II Catholic University of Lublin and earned a PhD in Medical Sciences from the Jagiellonian University Medical College, Bartłomiej has nearly two decades of experience in drug discovery. His expertise spans recombinant protein production, process scale-up, technology transfer, and protein analytics, alongside contributions to patents and peer-reviewed publications.

As Director of Drug Discovery & Early Development, he has built the department’s organisational structure, fostered an innovation-driven environment, and assembled a multidisciplinary team delivering results in oncology and CNS.

Bartłomiej is the co-creator of strategic partnerships with US-based companies and has overseen the transfer of two innovative compounds into first-in-human clinical trials, translating scientific vision into tangible therapeutic progress.

Lead Scientist CNS

Marcin Kołaczkowski

Dean of the Faculty of Pharmacy at the Jagiellonian University Medical College, Marcin is a medicinal chemist and neuropharmacologist with more than 20 years of academic and industry collaboration experience. He has authored over 100 peer-reviewed publications, is co-inventor on eight patents, and is recognised internationally for his work on GPCR targets.

He co-founded the Drug Discovery and Development Master’s programme at the Faculty of Pharmacy, creating a bridge between academia and the pharmaceutical industry. His research integrates medicinal and computational chemistry to drive translational drug discovery.

Currently, his work focuses on multimodal GPCR ligands for psychotic symptoms in Alzheimer’s disease and schizophrenia, as well as pioneering biased agonists of serotonergic receptors with strong antidepressant and anti-parkinsonian potential.

Head of Computational & Scientific Analysis

Marcin Feder

Founder of Adamed’s In Silico Laboratory, Marcin has spent over a decade applying computational modelling to sharpen structure–activity relationships, accelerate learning cycles, and improve go/no-go decision-making. His pragmatic approach blends advanced modelling with clear-sighted programme strategy.

As Head of Computational & Scientific Analysis, he leads a multidisciplinary team of molecular modellers, bioinformaticians, and data specialists, setting research strategy, implementing analytical systems, and monitoring technological trends.

His leadership has been central to advancing Adamed’s pipeline across therapeutic areas, ensuring that computation directly supports faster, smarter drug development.

Head of Preclinical Development

Dariusz Pawelec

A microbiologist with a PhD in Biological Sciences from the University of Warsaw, Dariusz has extensive expertise in molecular biology and preclinical development for innovative and value-added generic drugs. His career spans academic and commercial laboratories in Poland and the Netherlands.

In 2001–2002, he co-founded Adamed’s Biological Laboratory, one of Poland’s first commercial research centres for novel drugs. Today, as Head of Preclinical Development, he applies decades of managerial and scientific experience to advancing biotechnology-driven projects.

Dariusz has led more than a dozen R&D programmes with strong applied outcomes and holds an Associate’s Certificate in Project Management from The George Washington University. His work has earned multiple awards for scientific and project leadership.

Head of Research Laboratory

Marcin Solga

Holding a doctorate in biochemistry and microbiology and an MBA, Marcin combines deep scientific expertise with strong business acumen. He has spent more than a decade leading pharmaceutical innovation and managing high-performance teams.

At Adamed Discovery, he heads the Research Laboratory, directing the development of novel active substances, advanced drug formulations, and cutting-edge manufacturing technologies. His team spans biotechnology, analytical, in vitro, and in vivo disciplines.

Marcin’s leadership turns ambitious concepts into practical medical solutions, ensuring that innovation translates seamlessly from the lab bench to real-world application.

Head of Cell Biology & In Vivo Research

Piotr Rózga

A biotechnology graduate from the Warsaw University of Life Sciences and Doctor of Medical Sciences from the Jagiellonian University Medical College, Piotr is a recognised authority on cancer biology and cell death signalling. He has led cell biology research at Adamed for nearly two decades.

As Head of Cell Biology & In Vivo Research, he directs studies that assess the potential of hit compounds and elucidate mechanisms of action for novel anticancer candidates. His expertise includes flow cytometry, cell sorting, confocal microscopy, and molecular target identification.

An inventor with multiple patents and a prolific author, Piotr continues to drive oncology research through innovative scientific strategies and the leadership of a high-impact biotechnology team.

Head of Biotechnology & Recombinant Proteins

Sebastian Pawlak

A biotechnology graduate from the University of Warsaw with a PhD in Biochemistry from the Polish Academy of Sciences, Sebastian specialises in protein engineering, monoclonal antibodies, and mRNA-based therapies. His doctoral work centred on engineering the specificity of restriction enzymes.

At Adamed, he leads the Biotechnology & Recombinant Proteins team, driving the development of innovative biologics for oncology from early design to clinical manufacturing. His role spans analytical development, process optimisation, and technology transfer.

Sebastian is co-author of numerous publications and patents, blending strong academic foundations with practical expertise to deliver cutting-edge biologics and strengthen Adamed’s position in oncology innovation.